In this investigation, we found that combination therapy with proglumide and a PD-1Ab altered the HCC tumor microenvironment by decreasing fibrosis and M2-TAMs, and increasing the influx of CD8+ T-cells into the tumors, rendering the tumors more responsive to immune checkpoint antibody therapy. This evidence concerns the gene CD8A and hepatocellular carcinoma.